666 related articles for article (PubMed ID: 19153832)
21. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
22. Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
Desplat V; Belloc F; Lagarde V; Boyer C; Melo JV; Reiffers J; Praloran V; Mahon FX
Cancer; 2005 Jan; 103(1):102-10. PubMed ID: 15558795
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Møller GM; Frost V; Melo JV; Chantry A
FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
[TBL] [Abstract][Full Text] [Related]
25. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
Brieger A; Boehrer S; Schaaf S; Nowak D; Ruthardt M; Kim SZ; Atadja P; Hoelzer D; Mitrou PS; Weidmann E; Chow KU
Biochem Pharmacol; 2004 Jul; 68(1):85-93. PubMed ID: 15183120
[TBL] [Abstract][Full Text] [Related]
26. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
Morotti A; Cilloni D; Messa F; Arruga F; Defilippi I; Carturan S; Catalano R; Rosso V; Chiarenza A; Pilatrino C; Guerrasio A; Taulli R; Bracco E; Pautasso M; Baraban D; Gottardi E; Saglio G
Cancer; 2006 Mar; 106(5):1188-96. PubMed ID: 16444746
[TBL] [Abstract][Full Text] [Related]
27. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
Desplat V; Lagarde V; Belloc F; Chollet C; Leguay T; Pasquet JM; Praloran V; Mahon FX
Cytometry A; 2004 Nov; 62(1):35-45. PubMed ID: 15468123
[TBL] [Abstract][Full Text] [Related]
28. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
29. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
Kawano T; Horiguchi-Yamada J; Iwase S; Akiyama M; Furukawa Y; Kan Y; Yamada H
Anticancer Res; 2004; 24(5A):2705-12. PubMed ID: 15517875
[TBL] [Abstract][Full Text] [Related]
30. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
31. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.
Dan S; Naito M; Tsuruo T
Cell Death Differ; 1998 Aug; 5(8):710-5. PubMed ID: 10200527
[TBL] [Abstract][Full Text] [Related]
32. Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death.
Moehring A; Wohlbold L; Aulitzky WE; van der Kuip H
Cell Death Differ; 2005 Jun; 12(6):627-36. PubMed ID: 15818402
[TBL] [Abstract][Full Text] [Related]
33. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
Lee SM; Bae JH; Kim MJ; Lee HS; Lee MK; Chung BS; Kim DW; Kang CD; Kim SH
J Pharmacol Exp Ther; 2007 Sep; 322(3):1084-92. PubMed ID: 17569822
[TBL] [Abstract][Full Text] [Related]
34. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
Xu R; Dong Q; Yu Y; Zhao X; Gan X; Wu D; Lu Q; Xu X; Yu XF
Leuk Res; 2006 Jan; 30(1):17-23. PubMed ID: 16023722
[TBL] [Abstract][Full Text] [Related]
35. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Pytel D; Wysocki T; Majsterek I
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
[TBL] [Abstract][Full Text] [Related]
36. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA
Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728
[TBL] [Abstract][Full Text] [Related]
37. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
Mc Gee MM; Campiani G; Ramunno A; Fattorusso C; Nacci V; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2001 Jan; 296(1):31-40. PubMed ID: 11123359
[TBL] [Abstract][Full Text] [Related]
38. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells.
Mao X; Yu CR; Li WH; Li WX
Cell Res; 2008 Aug; 18(8):879-88. PubMed ID: 18663379
[TBL] [Abstract][Full Text] [Related]
39. Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate.
Park J; Kim S; Oh C; Yoon SS; Lee D; Kim Y
Biochem Biophys Res Commun; 2005 Oct; 336(3):942-51. PubMed ID: 16157305
[TBL] [Abstract][Full Text] [Related]
40. Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
Alessandro R; Fontana S; Giordano M; Corrado C; Colomba P; Flugy AM; Santoro A; Kohn EC; De Leo G
J Cell Physiol; 2008 Apr; 215(1):111-21. PubMed ID: 17924401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]